18178 Novel Induction Options in AML: Assessing the Implications for HCT-Eligible Patients

In this activity, experts in acute myeloid leukemia (AML) guide you through the science that supports the rapid integration of newer induction regimens into the care of AML patients who are eligible for hematopoietic stem cell transplantation (HCT), while offering expert thoughts on what a more diverse selection of induction options means for patients who have the greatest need for alternative treatments, including those with high-risk disease, older individuals who are fit for intensive therapy, or patients with molecular aberrations/mutations conferring a poor prognosis.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists and BMT nurse specialists, and other clinicians involved in the care of patients undergoing HCT.

Learning Objectives

  1. Summarize the current role and challenges of HCT and induction therapy in AML, including in elderly and high-risk patients
  2. Describe new evidence on novel induction strategies in AML such as novel cytotoxic or targeted strategies
  3. Select personalized, safe induction strategies for transplant eligible patients with AML who may not benefit from induction with standard 7+3
Additional information

Contact

Name: 
Michelle Stubley
Phone Number: 
+1 (414) 955-4900
Email: 
mstubley@mcw.edu
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
03/22/2018
Course expires: 
02/21/2019
Cost:
$0.00
Part of: 
PeerView Enduring Material from Tandem Meetings 2018

Jorge E. Cortes, MD

Jane and John Justin Distinguished Chair in Leukemia Research

Chief, CML & AML Sections

Deputy Chair, Department of Leukemia

The University of Texas MD Anderson Cancer Center

Houston, Texas

 

Stephen A. Strickland, MD, MSCI

Hematology Clinical Service Line Chief

Clinical Director, Acute Leukemia

Assistant Professor of Medicine

Vanderbilt University Medical Center

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee

 

 

All persons in control of content have no relevant financial relationships to disclose.

Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.